R&D Spending Showdown: Gilead Sciences, Inc. vs Sarepta Therapeutics, Inc.

R&D Spending: A Tale of Two Biotech Giants

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Gilead Sciences, Inc. and Sarepta Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Gilead Sciences consistently outspent Sarepta, with its R&D expenses peaking at approximately $6.9 billion in 2023, a staggering 690% increase compared to Sarepta's $877 million in the same year. This trend highlights Gilead's aggressive strategy to maintain its leadership in the biotech sector. Meanwhile, Sarepta's steady increase in R&D spending, growing nearly tenfold from 2014 to 2023, underscores its commitment to innovation despite its smaller scale. This financial commitment reflects the broader industry trend where R&D investment is crucial for developing groundbreaking therapies and maintaining competitive advantage.